475 related articles for article (PubMed ID: 17414440)
21. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
22. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies.
Gutzmer R; Kaspari M; Brodersen JP; Mommert S; Völker B; Kapp A; Werfel T; Kiehl P
Histopathology; 2002 Dec; 41(6):510-8. PubMed ID: 12460203
[TBL] [Abstract][Full Text] [Related]
23. S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: a totally dedifferentiated malignant melanoma?
Laskin WB; Knittel DR; Frame JN
Am J Clin Pathol; 1995 Jun; 103(6):772-3. PubMed ID: 7785665
[No Abstract] [Full Text] [Related]
24. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases.
Thies A; Berlin A; Brunner G; Schulze HJ; Moll I; Pfüller U; Wagener C; Schachner M; Altevogt P; Schumacher U
Cancer Lett; 2007 Apr; 248(1):68-80. PubMed ID: 16822608
[TBL] [Abstract][Full Text] [Related]
25. Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful?
Karimipour DJ; Lowe L; Su L; Hamilton T; Sondak V; Johnson TM; Fullen D
J Am Acad Dermatol; 2004 May; 50(5):759-64. PubMed ID: 15097961
[TBL] [Abstract][Full Text] [Related]
26. KBA.62: a useful marker for primary and metastatic melanomas.
Pagès C; Rochaix P; al Saati T; Valmary-Degano S; Boulinguez S; Launay F; Carle P; Lauwers F; Payoux P; Le Guellec S; Brousset P; Lamant L
Hum Pathol; 2008 Aug; 39(8):1136-42. PubMed ID: 18495211
[TBL] [Abstract][Full Text] [Related]
27. False-positive cells in sentinel lymph nodes.
Brennick JB; Yan S
Semin Diagn Pathol; 2008 May; 25(2):116-9. PubMed ID: 18697715
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.
Reinke S; Königer P; Herberth G; Audring H; Wang H; Ma J; Guo Y; Sterry W; Trefzer U
Am J Dermatopathol; 2005 Oct; 27(5):401-6. PubMed ID: 16148409
[TBL] [Abstract][Full Text] [Related]
29. Expression of melanoma-associated antigens in short-term melanoma cultures detected by RT-PCR and subsequent ELISA.
Hofbauer GF; Dummer R; Laine E; Burg G
Arch Dermatol Res; 1998 Aug; 290(8):458-61. PubMed ID: 9763311
[No Abstract] [Full Text] [Related]
30. Melan A and S100 protein immunohistochemistry in feline melanomas: 48 cases.
Ramos-Vara JA; Miller MA; Johnson GC; Turnquist SE; Kreeger JM; Watson GL
Vet Pathol; 2002 Jan; 39(1):127-32. PubMed ID: 12102204
[TBL] [Abstract][Full Text] [Related]
31. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
32. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.
Orchard GE
Histochem J; 2000 Aug; 32(8):475-81. PubMed ID: 11095072
[TBL] [Abstract][Full Text] [Related]
33. Psammomatous malignant melanoma arising in an intradermal naevus.
Monteagudo C; Ferrández A; González-Devesa M; Llombart-Bosch A
Histopathology; 2001 Nov; 39(5):493-7. PubMed ID: 11737307
[TBL] [Abstract][Full Text] [Related]
34. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients.
Enk CD; Lotem M; Gimon Z; Hochberg M
Melanoma Res; 2004 Oct; 14(5):361-5. PubMed ID: 15457091
[TBL] [Abstract][Full Text] [Related]
35. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation.
Hoang MP; Prieto VG; Burchette JL; Shea CR
J Cutan Pathol; 2001 Sep; 28(8):400-6. PubMed ID: 11493377
[TBL] [Abstract][Full Text] [Related]
36. Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma?
Kucher C; Zhang PJ; Acs G; Roberts S; Xu X
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):324-7. PubMed ID: 16932024
[TBL] [Abstract][Full Text] [Related]
37. Is MAGE-1 expression in metastatic malignant melanomas really helpful?
Gajjar NA; Cochran AJ; Binder SW
Am J Surg Pathol; 2004 Jul; 28(7):883-8. PubMed ID: 15223957
[TBL] [Abstract][Full Text] [Related]
38. Acral lentiginous melanoma: an immunohistochemical study of 20 cases.
Kim YC; Lee MG; Choe SW; Lee MC; Chung HG; Cho SH
Int J Dermatol; 2003 Feb; 42(2):123-9. PubMed ID: 12709000
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of isolated immunohistochemically positive cells in sentinel lymph nodes of melanoma patients.
Murali R; Thompson JF; Shaw HM; Scolyer RA
Am J Surg Pathol; 2008 Jul; 32(7):1106-7; author reply 1107-8. PubMed ID: 18521043
[No Abstract] [Full Text] [Related]
40. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma.
Mocellin S; Del Fiore P; Guarnieri L; Scalerta R; Foletto M; Chiarion V; Pilati P; Nitti D; Lise M; Rossi CR
Int J Cancer; 2004 Sep; 111(5):741-5. PubMed ID: 15252844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
